Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Renal inflammation is one of the main drivers of kidney damage progression in diabetic kidney disease (DKD). In vitro studies and animal models suggest that the cardiorenal-metabolic benefits of SGLT2 inhibitors in DKD may be linked to an anti-inflammatory renal effect. However, this hypothesis has not been confirmed in real-world settings. Thus, our main aim was to evaluate whether SGLT2 inhibitor therapy in patients with albuminuric DKD modified urinary levels of inflammation-related biomarkers.
We conducted a prospective observational study in patients with DKD and albuminuria >30 mg/g creatinine who started SGLT2 inhibitors for clinical indications. Urinary levels of pro- and anti-inflammatory cytokines were measured at baseline, and at 1, 3, and 6 months after SGLT2 initiation.
72 patients were included. Median age was 69 years; 29.2% were women. At baseline, eGFR was 52 mL/min/1.73m², median albuminuria was 838 mg/g (59.9% A3), BMI 30.1 kg/m², and HbA1c 6.8%; 83% were on ACEi/ARB, 63.8% on metformin, 26.8% on GLP-1 RA, and 27.8% on insulin. Dapagliflozin was started in 68 patients and empagliflozin in 4. A significant reduction in median albuminuria was observed at 6 months, with an eGFR decline <20%.
After one month of SGLT2 therapy, urinary levels of key pro-inflammatory cytokines (IL-6, IL-7, MCP-1, IFN-γ, CCL8, CXCL8, CXCL9, CXCL10, CXCL11, and VEGF-A) decreased significantly, and most remained lower at 3 and 6 months. No significant changes were seen in anti-inflammatory cytokines (IL-10, IL-4, IL-13, EGF, CSF2). SGLT2 inhibitors did not modify urinary levels of IL-18, IL-1β, IL-2, TNF, or IL-15 at any time point.
Reduction in urinary pro-inflammatory cytokines was not correlated with changes in albuminuria at one month (IL-6 rho 0.048, MCP-1 rho -0.078, IL-7 rho -0.070, VEGF-A rho 0.025), nor with baseline antidiabetic therapy (metformin, GLP-1 RA, insulin).
SGLT2 inhibitor therapy in patients with albuminuric DKD was associated with reduced renal inflammation, reflected by lower urinary excretion of pro-inflammatory cytokines. This effect was independent of changes in albuminuria and did not affect anti-inflammatory cytokine excretion.
These results were previously presented at the 2025 Congress of the Spanish Society of Nephrology (Oviedo, Spain).
